Source: Kemper et al., (2022). Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; e2022058859. 10.1542/peds.2022-058859

Click here to view to the AAP News Press Release

This updates and replaces the 2004 American Academy of Pediatrics (AAP) clinical practice guideline for the management and prevention of hyperbilirubinemia in the newborn infant ≥35 weeks’ gestation. The previous guidelines included 10 recommendations. The revised 2022 guidelines includes 25 Key Action Statements (KAS) along with a key driver diagram and QI metrics to guide QI efforts to eliminate kernicterus. This clinical practice guideline, like the previous one, addresses issues of prevention, risk assessment, monitoring, and treatment. The associated technical report reviews the evidence used to develop the guidelines.

Find the guidelines here: Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.

Find the associated Technical Report here: Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation

Find the phototherapy guidelines here (subscription required): Predicting the Need for Phototherapy After Discharge: Update for 2022 Phototherapy Guidelines